Keyword Analysis & Research: gsk836


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
gsk8361.640.76388576

Keyword Research: People who searched gsk836 also searched

Keyword CPC PCC Volume Score
gsk8361.930.3105873

Search Results related to gsk836 on Search Engine

  • GSK presents promising new data for bepirovirsen, an …

    gsk.com

    https://www.gsk.com/en-gb/media/press-releases/gsk-presents-promising-new-data-for-bepirovirsen-an-investigational-treatment-for-chronic-hepatitis-b/

    WEBJun 25, 2022 · GSK plc today announced promising interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks’ treatment in people with chronic hepatitis B (CHB).

    DA: 63 PA: 71 MOZ Rank: 40

  • GSK receives US FDA Fast Track designation for bepirovirsen in …

    gsk.com

    https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/

    WEBFeb 12, 2024 · GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB).

    DA: 6 PA: 83 MOZ Rank: 53

  • Novel Antivirals in Clinical Development for Chronic Hepatitis B

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235765/

    WEBJun 18, 2021 · ISIS505358/GSK3228836 (GSK836) is a type of non-GaiNAc-conjugated ASO. GSK836 given subcutaneously on days 1, 4, 8, 11, 15, and 22 led to significant reductions in HBsAg, with bigger magnitudes of decline in NA-treated patients (2.51 logs) compared to NA-naïve patients (1.56 logs).

    DA: 58 PA: 59 MOZ Rank: 23

  • Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B …

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa2210027

    WEBNov 8, 2022 · Bepirovirsen (GSK3228836), a 2′-O-methoxyethyl modified antisense oligonucleotide, targets all HBV RNAs, including HBV messenger RNA and pregenomic …

    DA: 37 PA: 1 MOZ Rank: 96

  • Hepatitis B: a new weapon against an old enemy - Nature

    nature.com

    https://www.nature.com/articles/s41591-021-01512-5

    WEBOct 12, 2021 · 6 Citations. 20 Altmetric. Metrics. New strategies based on nucleic acid technologies are being exploited to treat chronic hepatitis B—a pilot clinical study of antisense oligonucleotide treatment...

    DA: 96 PA: 85 MOZ Rank: 51

  • How to achieve functional cure of HBV: Stopping NUCs, adding …

    sciencedirect.com

    https://www.sciencedirect.com/science/article/pii/S0168827821022339

    WEBJun 1, 2022 · The only naked ASO in clinical development (GSK836) led to rapid and profound HBsAg reductions (3-4 log reduction within 28 days) followed by ALT elevations, thought to represent HBV-specific immune reconstitution. 60 Four patients in that study lost HBsAg by Day 29 and 2 remained HBsAg negative for more than 3 months.

    DA: 24 PA: 11 MOZ Rank: 6

  • GSK presents promising phase 2a data for chronic hepatitis B treatment

    gsk.com

    https://us.gsk.com/en-us/media/press-releases/gsk-presents-promising-phase-2a-data-for-chronic-hepatitis-b-treatment/

    WEBAug 28, 2020 · GSK today announced that GSK’836 (GSK3228836), an investigational antisense oligonucleotide, showed marked reductions in hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA compared with placebo after four weeks treatment in people with chronic hepatitis B on stable nucleoside or nucleotide analogue (NA) therapy and in patients who wer...

    DA: 97 PA: 47 MOZ Rank: 35

  • Positive data for bepirovirsen from B-Clear phase IIb trial ... - GSK

    gsk.com

    https://www.gsk.com/en-gb/media/press-releases/positive-data-for-bepirovirsen-from-b-clear-phase-iib-trial/

    WEBNov 8, 2022 · GSK plc (LSE/NYSE: GSK) today announced the publication of positive end of study results from the B-Clear phase IIb trial evaluating the safety and efficacy of bepirovirsen for the treatment of chronic hepatitis B (CHB) in …

    DA: 49 PA: 39 MOZ Rank: 77

  • Ionis announces presentation of positive Phase 2b data for …

    ionispharma.com

    https://ir.ionispharma.com/news-releases/news-release-details/ionis-announces-presentation-positive-phase-2b-data-chronic

    WEBCARLSBAD, Calif., June 25, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen (formerly IONIS-HBV Rx ), an investigational antisense medicine for the treatment of patients with chronic hepatitis B viru...

    DA: 72 PA: 80 MOZ Rank: 46

  • Bepirovirsen | Ionis Pharmaceuticals, Inc.

    ionispharma.com

    https://www.ionispharma.com/medicines/ionis-hbv/

    WEBBepirovirsen, formerly known as IONIS-HBV Rx and GSK3228836, is an investigational antisense medicine designed to inhibit the production of viral proteins associated with hepatitis B virus (HBV).

    DA: 28 PA: 84 MOZ Rank: 85